Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects

Molecular Cancer

Review

Meili Sun¹  Huan Shi²  Lin Liu²  Zhehai Wang² 

[1] Department of Oncology, Jinan Central Hospital affiliated to Shandong University, No. 105, Jie Fang Road, 250013, Jinan, Shandong, P.R, China;Department of Oncology, Shandong Cancer Hospital and Institute, No. 440 Jiyan Road, 250117, Jinan, Shandong, P.R., China;

关键词: Adoptive transfer;    Chimeric antigen receptor;    Gene transfer;    T cells;   

DOI  :  10.1186/1476-4598-13-219

 received in 2014-06-12, accepted in 2014-09-17,  发布年份 2014

来源: Springer

【 摘 要 】

Chimeric antigen receptors (CARs) are recombinant receptors that combine the specificity of an antigen-specific antibody with the T-cell’s activating functions. Initial clinical trials of genetically engineered CAR T cells have significantly raised the profile of T cell therapy, and great efforts have been made to improve this approach. In this review, we provide a structural overview of the development of CAR technology and highlight areas that require further refinement. We also discuss critical issues related to CAR therapy, including the optimization of CAR T cells, the route of administration, CAR toxicity and the blocking of inhibitory molecules.

【 授权许可】

Unknown   
© Shi et al.; licensee BioMed Central Ltd. 2014. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.